Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child
Hongyu Huang, Jiao Chen, Lei Ye, Dan Yu · 2026
Read Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child by Hongyu Huang, Jiao Chen, Lei Ye, Dan Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13319008.txt.
Description
Hongyu Huang and colleagues give a 2026 case report of reversible bone marrow disease caused by sodium valproate in a child with epilepsy. A nine-year-old boy developed low counts across all blood lines after six months on the drug. His haemoglobin was 77 g/L, and platelets were 83 × 109/L at presentation. Marrow testing confirmed myelodysplastic syndrome.
Doctors cut his valproate dose to 250 mg per day and added lacosamide. Within three months his blood counts returned to normal. A repeat marrow exam showed the abnormal features had cleared. Seizure control held without relapse through the reported period. The authors stress the dose-dependent nature of this rare harm. They urge regular blood monitoring for children on valproate.
Catalog record
| CREATOR | Hongyu Huang, Jiao Chen, Lei Ye, Dan Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12598 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |